Navigation Links
Medco Announces Date for Second-Quarter 2009 Financial Results
Date:6/30/2009

FRANKLIN LAKES, N.J., June 30 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) plans to announce its second-quarter 2009 financial results in a press release before the market opens on Wednesday, July 29, 2009.

Following the release, management will hold a conference call to review the financial results, outlook and related matters at 8:30 a.m. ET.

To access the live conference call via telephone:

Dial in: (800) 949-5383 from inside the U.S., or (706) 679-3440 from outside the U.S.

To access the live webcast:

Visit the Investor Relations section at www.medco.com/investor.

For a replay of the call:

A replay of the call will be available after the event on July 29, 2009 through August 13, 2009. Dial in: (800) 642-1687 from inside the U.S., or (706) 645-9291 from outside the U.S. Please use passcode 15222258.

About Medco

Medco Health Solutions, Inc (NYSE: MHS) is a leading health care company, serving the needs of more than 60 million people. Medco, the world's most advanced pharmacy(R), provides clinically driven pharmacy services designed to improve the quality of care and lower total health care costs for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by Medicare Part D Prescription Drug Plans. Through its unique Medco Therapeutic Resource Centers(R) and the Accredo Health Group, Medco's Specialty Pharmacy, the company is creating innovative models for the care of patients with chronic and complex conditions. Medco is a leader in the emerging field of personalized medicine and in applying evidence-based protocols to elevate the practice of pharmacy - a key element in reforming America's health care system. Medco is ranked number 45 on the Fortune 500 list, with 2008 revenues of more than $51 billion. For more information about Medco, go to http://www.medcohealth.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
2. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
3. Medco Announces Date for Third-Quarter 2007 Financial Results
4. Six Olympic Legends Battling Chronic Diseases Lead Revolution in Advancing Pharmacy Care as Medco Launches the Tour of Champions
5. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
6. Medco to Build Worlds Largest, Most Advanced Automated Pharmacy in Central Indiana
7. Medco Elects Myrtle Potter, William Roper to Board of Directors
8. Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference
9. Medco Announces Two-For-One Stock Split
10. URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards
11. MedcomSoft appoints former U.S. presidential health advisor, James Haveman, to health Care advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... A quote from Dr. Edward Hallowell, host of CRN International’s “Distraction” podcast ... glimpse into the mind of those people with ADHD. , Dr. Hallowell, a child ... people with ADHD as having “Ferrari engines for a brain, with bicycle brakes.” , ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff ... located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, ... treatment for a brain tumor. , Jason Bauer and his family are longtime ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm ... Boroughs, is launching a charity drive to raise funds that will benefit the Marine ... of marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry ... through user experience. , BOC Global Events & Training Group is a professional ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
Breaking Medicine Technology: